Experimental study demonstrates an ultrasensitive electrochemiluminescence biosensor for miRNA-21 detection using nanoconfined MOFs, highlighting potential for early clinical disease screening.
Simultaneously overcoming aggregation‐induced quenching and sluggish interfacial kinetics remains a pivotal challenge in electrochemiluminescence. Herein, we have successfully synthesized dual‐functional nanoconfined metal–organic frameworks encapsulating Pt‐A‐COOH complexes (Pt@UiO‐67 MOFs) as electrochemiluminescence emitters and co‐reaction accelerators by a ligand‐similarity‐driven doping strategy. The dual‐functional Pt@UiO‐67 MOFs unlocked aggregation‐induced electrochemiluminescence and expedited interfacial reaction kinetics by spatial nanoconfinement, the electrochemiluminescence efficiency of which was ca . 5.4‐fold higher than that of the Pt‐A‐COOH as co‐reactant to catalyze the decomposition of S 2 O 8 2− . Density functional theory calculations and electrochemical electron paramagnetic resonance measurements indicated that the nanoconfinement structure reduced the activation energy barrier for the reduction of S 2 O 8 2− , thereby optimizing the kinetics of SO 4 •− (0.92 eV) and OH • (0.63 eV) radical generation. Based on the Pt@UiO‐67 MOFs and DNAzyme motor, the ultrasensitive biosensor has been successfully constructed and had wide linear range (from ∼10 aM to ∼10 nM) and an ultralow detection limit of ∼4.1 aM. In the preliminary proof‐of‐concept evaluation using acute kidney injury clinical samples, the assay results had excellent concordance with those of quantitative reverse transcription polymerase chain reaction. This work provides a paradigm integrating supramolecular engineering with DNA nanotechnology, which paves the way for sensitive biodetection and preliminary clinical screening.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: